These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31669077)

  • 1. Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
    Kósa F; Kunovszki P; Borsi A; Iliás Á; Palatka K; Szamosi T; Vincze Á; Molnár T; Lakatos PL
    Dig Liver Dis; 2020 Mar; 52(3):274-280. PubMed ID: 31669077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation.
    Viazis N; Koukouratos T; Anastasiou J; Giakoumis M; Triantos C; Tsolias C; Theocharis G; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2015 Apr; 27(4):436-41. PubMed ID: 25874518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
    Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients.
    Baert F; Glorieus E; Reenaers C; D'Haens G; Peeters H; Franchimont D; Dewit O; Caenepeel P; Louis E; Van Assche G;
    J Crohns Colitis; 2013 Mar; 7(2):154-60. PubMed ID: 22537637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Inflamm Bowel Dis; 2016 Apr; 22(4):870-9. PubMed ID: 26818419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
    Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
    Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Aliment Pharmacol Ther; 2018 Mar; 47(5):596-604. PubMed ID: 29239001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
    Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab.
    Yokoyama K; Yamazaki K; Katafuchi M; Ferchichi S
    Adv Ther; 2016 Nov; 33(11):1947-1963. PubMed ID: 27664107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.
    Osamura A; Suzuki Y
    Dig Dis Sci; 2018 Jan; 63(1):204-208. PubMed ID: 29209921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spacing the Administration Interval of Anti-TNF Agents: A Valid Strategy for Patients with Inflammatory Bowel Disease?
    Torres P; Cañete F; Núñez L; Aguilar A; Mesonero F; Calafat M; Fernández C; Teniente A; Mañosa M; López-Sanromán A; Domènech E
    Dig Dis Sci; 2020 Jul; 65(7):2036-2043. PubMed ID: 31858325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience.
    Peyrin-Biroulet L; Salleron J; Filippi J; Reenaers C; Antunes O; Filipe V; Louis E; Hébuterne X; Roblin X
    J Crohns Colitis; 2016 May; 10(5):516-24. PubMed ID: 26802084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease.
    Kaniewska M; Rosołowski M; Rydzewska G
    Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV; Jaganathan S; Bedenbaugh AV; Palmer L; Schwartz DA
    Curr Med Res Opin; 2014 Sep; 30(9):1821-6. PubMed ID: 24884302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.
    Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Wittmann T
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):265-9. PubMed ID: 23012667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.